Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis.

These limitations may contribute in part to the fact that while anemic patients had numerically higher total healthcare and total medical costs than patients without anemia, these differences did not reach statistical significance; the lack of significance on these endpoints prevents definitive conclusion that anemic patients universally incur higher healthcare costs.

also in 111,027 other papers